TG Therapeutics initiates study of ublituximab/ PI3K Delta inhibitor combo

|About: TG Therapeutics, Inc. (TGTX)|By:, SA News Editor

TG Therapeutics (TGTX +10.4%) jumps after announcing the initiation of a Phase 1 trial to test the efficacy and safety of a TG-1101/ TGR-1202 combo in relapsed and/or refractory CLL and NHL.

In other company news, TGTX opens the first expansion cohort in a TGR-1202 dose escalation study — no MTD has yet been determined. (PR)